GSK Commits $30B U.S. Investment Amid Trump’s UK Visit

British pharmaceutical giant GSK Plc has pledged to invest up to $30 billion in the U.S. over the next five years, a move announced during President Donald Trump's visit to the UK. The commitment comes as TRUMP pushes for increased domestic drug manufacturing to counter high costs for American consumers.

GSK's U.S. operations account for 50% of its annual revenue, making the investment strategically significant. The company plans to allocate $1.2 billion toward a new biologics facility in Pennsylvania, focusing on respiratory and cancer treatments, with construction set to begin in 2026.

The remaining funds will expand existing operations, though specific allocations remain undisclosed. U.S. Commerce Secretary Howard Lutnick hailed the pledge as a 'landmark investment' that will create skilled jobs and bolster domestic medicine production.